CLYM Q4 2023 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena

CLYMClimb Bio, Inc.

$522M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$5M

Net Income

-$4M

EPS (Diluted)

$-0.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$947,000

Free Cash Flow

-$947,000

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$110M

Total Liabilities

$3M

Stockholders' Equity

$108M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$5M	-$10M	+46.4%
Net Income	-$4M	-$8M	+53.1%